Skip to main content
SpringerLink
Log in

Epidemiology and Outcomes of Regimen-Related Toxicities

  • Chapter
  • First Online:
Pathobiology of Cancer Regimen-Related Toxicities

  • 723 Accesses

Abstract

Treatment-related toxicities are common among patients with cancer; they lead to poor clinical outcomes, reduced functional status, higher consumption of healthcare resources, and excess costs. The toxicity, its risk and outcomes, varies depending on the regimen received. In this chapter, we describe the epidemiology of toxicities commonly observed among patients receiving current treatment regimens.

Note: Each toxicity mentioned in the chapter could also be indexed. These include the following: hypersensitivity reaction, nausea, vomiting, neurotoxicity, mucositis, diarrhea, alopecia, acral erythema, hand–foot syndrome, nail toxicity, skin rash, dermatitis, neutropenia, anemia, thrombocytopenia, infection, fatigue, hemorrhage, cardiac toxicity, hypertension, left ventricular dysfunction, heart failure, cardiac ischemia, venous thrombo-embolism, xerostomia, osteonecrosis, osteoradionecrosis, graft-versus-host disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weiner MG, et al. Estimating the costs of chemotherapy-associated adverse event clusters. Health Serv Outcomes Res Method. 2007;7(1–2):1–21.

    Article  Google Scholar 

  2. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Exp Rev Clin Immunol. 2011;7(1):55–63.

    Article  CAS  Google Scholar 

  3. Makrilia N, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010;2010.

    Google Scholar 

  4. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009;102(3):179–87 [quiz 187–9, 222].

    Article  PubMed  Google Scholar 

  5. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.

    Article  PubMed  CAS  Google Scholar 

  6. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23): 2482–94.

    Article  PubMed  CAS  Google Scholar 

  7. Hesketh PJ, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103–9.

    PubMed  CAS  Google Scholar 

  8. Grunberg SM, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art. Support Care Cancer. 2011;19 Suppl 1:S43–7.

    Article  PubMed  Google Scholar 

  9. National Compresensive Cancer Network (NCCN). Clinical practice guidelines in oncology (NCCN guidelines): antiemesis. Version 1.2012; 2011.

    Google Scholar 

  10. Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678–85.

    Article  Google Scholar 

  11. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29(5 Suppl 15):11–20.

    Article  PubMed  CAS  Google Scholar 

  12. Park SB, et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15(29):3081–94.

    Article  PubMed  CAS  Google Scholar 

  13. Stubblefield MD, et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7 Suppl 5:S1–26 [quiz S27–8].

    PubMed  Google Scholar 

  14. Sonis ST, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl): 1995–2025.

    Article  PubMed  Google Scholar 

  15. Elting LS, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110–20.

    Article  PubMed  Google Scholar 

  16. Elting LS, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704–13.

    Article  PubMed  Google Scholar 

  17. Elting LS, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–9.

    Article  PubMed  Google Scholar 

  18. Wadler S. Treatment guidelines for chemotherapy-induced diarrhea. Gastroenterol Endosc News 2004:29–33.

    Google Scholar 

  19. Maroun JA, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007;14(1):13–20.

    Article  PubMed  CAS  Google Scholar 

  20. Miller RC, et al. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys. 1998;41(3):593–8.

    Article  PubMed  CAS  Google Scholar 

  21. Keefe DM, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–31.

    Article  PubMed  CAS  Google Scholar 

  22. Al-Dasooqi N, et al. Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs. 2009;27(2):173–8.

    Article  PubMed  CAS  Google Scholar 

  23. Al-Dasooqi N, et al. HER2 targeted therapies for cancer and the gastrointestinal tract. Curr Drug Targets. 2009;10(6):537–42.

    Article  PubMed  CAS  Google Scholar 

  24. Loriot Y, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5(5):268–78.

    Article  PubMed  CAS  Google Scholar 

  25. Motzer RJ, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–24.

    Article  PubMed  CAS  Google Scholar 

  26. Fanucchi MP, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(31):5025–33.

    Article  PubMed  CAS  Google Scholar 

  27. Escudier B, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–8.

    Article  PubMed  CAS  Google Scholar 

  28. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80.

    Article  PubMed  CAS  Google Scholar 

  29. Crown JP, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2008;112(2):317–25.

    Article  PubMed  CAS  Google Scholar 

  30. Geyer CE, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.

    Article  PubMed  CAS  Google Scholar 

  31. Fukuoka M, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237–46.

    Article  PubMed  CAS  Google Scholar 

  32. Herbst RS, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol. 2004;22(5):785–94.

    Article  PubMed  CAS  Google Scholar 

  33. Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.

    Article  PubMed  CAS  Google Scholar 

  34. Herbst RS, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892–9.

    Article  PubMed  CAS  Google Scholar 

  35. Dranitsaris G, Maroun J, Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol. 2005;19(2):83–7.

    PubMed  Google Scholar 

  36. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367–98 [quiz 399–400].

    Article  PubMed  CAS  Google Scholar 

  37. Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol. 2006;33(1):86–97.

    Article  PubMed  CAS  Google Scholar 

  38. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24(3):457–61.

    Article  PubMed  CAS  Google Scholar 

  39. Chu D, et al. Risk of hand–foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176–86.

    Article  PubMed  CAS  Google Scholar 

  40. Chu D, et al. Risk of hand–foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7(1):11–9.

    Article  PubMed  Google Scholar 

  41. Balagula Y, Lacouture ME, Cotliar JA. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol. 2010;8(4):149–61.

    PubMed  CAS  Google Scholar 

  42. Roe E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006;55(3):429–37.

    Article  PubMed  Google Scholar 

  43. Burtness B, et al. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw. 2009;7 Suppl 1:S5–21 [quiz S22–4].

    PubMed  Google Scholar 

  44. Jia Y, et al. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol. 2009;7(6):211–7.

    PubMed  CAS  Google Scholar 

  45. Su X, et al. Risk of high-grade skin rash in cancer patients treated with cetuximab—an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology. 2009;77(2):124–33.

    Article  PubMed  CAS  Google Scholar 

  46. Lacouture ME, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009;114(3):485–93.

    Article  PubMed  CAS  Google Scholar 

  47. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003;1(1):23–35.

    Article  PubMed  Google Scholar 

  48. National Compresensive Cancer Network (NCCN). Clinical practice guidelines in oncology (NCCN guidelines): myeloid growth factors. Version 1.2011; 2011.

    Google Scholar 

  49. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616–34.

    Article  PubMed  CAS  Google Scholar 

  50. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):11S–26.

    Article  PubMed  Google Scholar 

  51. Barrett-Lee PJ, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70(1):34–48.

    Article  PubMed  CAS  Google Scholar 

  52. National Compresensive Cancer Network (NCCN). Clinical practice guidelines in oncology (NCCN guidelines): cancer- and chemotherapy-induced anemia. Version 2.2012; 2011.

    Google Scholar 

  53. Ludwig H, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–306.

    Article  PubMed  Google Scholar 

  54. Curt GA, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5(5):353–60.

    Article  PubMed  CAS  Google Scholar 

  55. Vogelzang NJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997;34 (3 Suppl 2):4–12.

    PubMed  CAS  Google Scholar 

  56. Cella D, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528–38.

    Article  PubMed  Google Scholar 

  57. Cella D, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15(6):979–86.

    Article  PubMed  CAS  Google Scholar 

  58. Hofman M, et al. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12 Suppl 1:4–10.

    Article  PubMed  Google Scholar 

  59. Kantarjian H, et al. The incidence and impact of thrombocytopenia in myelodysplastic ­syndromes. Cancer. 2007;109(9):1705–14.

    Article  PubMed  CAS  Google Scholar 

  60. Goldberg GL, et al. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol. 1994;12(11):2317–20.

    PubMed  CAS  Google Scholar 

  61. Wu Y, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007. Clin Ther. 2009;31(Pt 2):2416–32.

    Article  PubMed  Google Scholar 

  62. Schiffer CA, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(5):1519–38.

    PubMed  CAS  Google Scholar 

  63. Elting LS, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137–46.

    PubMed  CAS  Google Scholar 

  64. Havrilesky LJ, et al. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007;107(2):211–8.

    Article  PubMed  Google Scholar 

  65. Hapani S, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010;79(1–2):27–38.

    Article  PubMed  CAS  Google Scholar 

  66. Keefe D, et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011;16(4):432–44.

    Article  PubMed  CAS  Google Scholar 

  67. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009;10(10):967–74.

    Article  PubMed  CAS  Google Scholar 

  68. Curigliano G, et al. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010;53(2):94–104.

    Article  PubMed  CAS  Google Scholar 

  69. Gottdiener JS, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758–63.

    Article  PubMed  CAS  Google Scholar 

  70. Ederhy S, et al. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011;80(3):369–79.

    Article  PubMed  Google Scholar 

  71. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

    Article  PubMed  CAS  Google Scholar 

  72. Spector NL, et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A. 2007;104(25):10607–12.

    Article  PubMed  CAS  Google Scholar 

  73. Azim H, Azim Jr HA, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev. 2009;35(7):633–8.

    Article  PubMed  CAS  Google Scholar 

  74. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11.

    Article  PubMed  CAS  Google Scholar 

  75. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  PubMed  CAS  Google Scholar 

  76. Liao L, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J. 2007;153(2):245–52.

    Article  PubMed  Google Scholar 

  77. Blecker S, et al. Hospice care and resource utilization in Medicare beneficiaries with heart failure. Med Care. 2011;49(11):985–91.

    Article  PubMed  Google Scholar 

  78. Nalluri SR, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–85.

    Article  PubMed  CAS  Google Scholar 

  79. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost. 2007;97(6):1031–6.

    PubMed  Google Scholar 

  80. Zangari M, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27(29):4865–73.

    Article  PubMed  CAS  Google Scholar 

  81. Bennett CL, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296(21):2558–60.

    Article  PubMed  CAS  Google Scholar 

  82. Hausheer FH, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33(1):15–49.

    Article  PubMed  CAS  Google Scholar 

  83. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990;66(6):1117–23.

    Article  PubMed  CAS  Google Scholar 

  84. Morrow GR, et al. Fatigue associated with cancer and its treatment. Support Care Cancer. 2002;10(5):389–98.

    Article  PubMed  Google Scholar 

  85. Jensen SB, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18(8):1039–60.

    Article  PubMed  CAS  Google Scholar 

  86. Jensen SB, et al. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol. 2008;44(2):162–73.

    Article  PubMed  CAS  Google Scholar 

  87. Connor NP, et al. Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck. Int J Radiat Oncol Biol Phys. 2006;65(4):1051–62.

    Article  PubMed  Google Scholar 

  88. Epstein JB, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck. 1999;21(1):1–11.

    Article  PubMed  CAS  Google Scholar 

  89. Harrison LB, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck. 1997;19(3):169–75.

    Article  PubMed  CAS  Google Scholar 

  90. List MA, et al. Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res. 1997;6(3):274–84.

    Article  PubMed  CAS  Google Scholar 

  91. List MA, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol. 1999;17(3): 1020–8.

    PubMed  CAS  Google Scholar 

  92. Nijdam WM, et al. Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery. Brachytherapy. 2008;7(4):343–50.

    Article  PubMed  Google Scholar 

  93. Peterson DE, et al. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer. 2010;18(8):1089–98.

    Article  PubMed  Google Scholar 

  94. Migliorati CA, et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer. 2010;18(8):1099–106.

    Article  PubMed  Google Scholar 

  95. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc. 2009;140(7):864–75.

    PubMed  CAS  Google Scholar 

  96. Estilo CL, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26(24): 4037–8.

    Article  PubMed  Google Scholar 

  97. Ferrara JL. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol. 2008;21(4):677–82.

    Article  PubMed  CAS  Google Scholar 

  98. Ferrara JL, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.

    Article  PubMed  CAS  Google Scholar 

  99. Flowers ME, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.

    Article  PubMed  CAS  Google Scholar 

  100. Arora M, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117(24):6714–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Section of Health Services Research, Department of Biostatistics, Unit 1411, The University of Texas M.D. Anderson Cancer Center, 301402, Houston, TX, 77230-1402, USA

    Linda S. Elting Dr. P.H., Yu-Chia Chang M.P.H. & Pratibha Parelkar M.P.H.

Authors
  1. Linda S. Elting Dr. P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Chia Chang M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pratibha Parelkar M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda S. Elting Dr. P.H. .

Editor information

Editors and Affiliations

  1. Brigham and Women’s Hospital, Francis Street 75, Boston, 01778, Massachusetts, USA

    Stephen T. Sonis

  2. Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, South Australia, Australia

    Dorothy M. Keefe

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Elting, L.S., Chang, YC., Parelkar, P. (2013). Epidemiology and Outcomes of Regimen-Related Toxicities. In: Sonis, S., Keefe, D. (eds) Pathobiology of Cancer Regimen-Related Toxicities. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5438-0_1

Download citation

Publish with us

Policies and ethics

Search

Navigation